Brought to you by:

Cell & Gene Therapy

Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Prasad’s replacement is “likely to fall further along the ‘right-to-try’ arm of the MAHA-RFK policy side,” Leerink analyst Mani Foroohar said.
Angus Liu Jul 31, 2025 9:10am
FDA
Favicon Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am
Clear out clearnance rubbish scrap heap

AstraZeneca drops lead TCR therapy from $200M Neogene buy

Jul 29, 2025 4:13am
timer sand clocks time

Arrowhead meets $100M milestone, awaits Sarepta payment

Jul 28, 2025 3:10pm
embryonic stem cells

Cell therapy biotech keeps adapting, selling 4 programs for $55M

Jul 28, 2025 10:52am
Graham

Elevidys fallout hasn't dented Roche's hopes for gene therapies

Jul 25, 2025 8:30am
More News
Fierce Pharma

FDA eyeing study requirements to confirm Elevidys safety: report

Jul 24, 2025 3:12pm

Galapagos builds island of cell therapies amid pipeline pruning

Jul 24, 2025 10:59am

Cell therapy biotech Adicet sheds 30% of staffers

Jul 24, 2025 10:20am

Rocket adjusts trajectory, laying off staff and narrowing focus

Jul 24, 2025 8:05am